RESUMO
Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to patients with limited disease after chemotherapy. In limited-disease and extensive-disease patients the median survival was 12 and 6 months respectively. The 2-year survival rate (life table) in limited-disease patients was 26%. Treatment morbidity was low. A prospective randomised trial is being undertaken to further evaluate the role of oral etoposide in combination chemotherapy.
Assuntos
Carcinoma de Células Pequenas/tratamento farmacológico , Etoposídeo/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Carcinoma de Células Pequenas/radioterapia , Doxorrubicina/uso terapêutico , Esquema de Medicação , Feminino , Humanos , Neoplasias Pulmonares/radioterapia , Masculino , Pessoa de Meia-Idade , Vincristina/uso terapêuticoRESUMO
The role of chemotherapy for patients with metastatic non-small-cell lung carcinoma (NSCCL) is controversial. A patient with intrathoracic metastatic NSCCL, who was treated by moderate dose cisplatin combination chemotherapy and who remained clinically free of disease more than 5 years after presentation, is described. This treatment has not previously been reported. A trial of moderate-dose cisplatin combination chemotherapy in selected patients with good performance status seems justified.